Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Pradaxa
Generic Name
Dabigatran Etexilate
Active Ingredient
Dabigatran EtexilateCategory
Other
Salt Form
Mesylate
Variants
6
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Pradaxa, you must consult a qualified healthcare professional.
| 40 mg/1 | PELLET | ORAL | 0597-0435 |
| 50 mg/1 | PELLET | ORAL | 0597-0440 |
| 150 mg/1 | PELLET | ORAL | 0597-0450 |
Detailed information about Pradaxa
Dabigatran Etexilate is a direct thrombin inhibitor (anticoagulant) used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and to treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE).
The dosage of dabigatran etexilate varies depending on the medical condition being treated and the patient's renal (kidney) function. Standard adult dosages include:
Dabigatran etexilate is approved for use in pediatric patients from birth to less than 18 years of age for the treatment of venous thromboembolism (VTE) and to prevent recurrent VTE. The dosage in children is strictly weight-based and often utilizes the oral pellet formulation. Healthcare providers use specific nomograms (dosing charts) to determine the exact mg/kg dose required. It is not recommended for children with a creatinine clearance (a measure of kidney function) below a certain threshold based on their age and size.
Because dabigatran is primarily cleared by the kidneys, renal function must be assessed before starting therapy and monitored at least annually.
While dabigatran is not heavily metabolized by the liver, patients with severe hepatic (liver) impairment or known coagulation disorders related to liver disease should avoid this medication, as it may increase the risk of bleeding.
Patients over the age of 75 often have naturally declining kidney function and a higher risk of bleeding. While no specific dose reduction is mandated solely for age, healthcare providers frequently monitor these patients more closely and may opt for the lower dose (110 mg in some regions, though 75 mg is the low-dose option in the US) if other risk factors are present.
If you miss a dose of dabigatran etexilate, take it as soon as you remember. However, if your next dose is less than 6 hours away, skip the missed dose and take the next one at your regular time. Do not take two doses at once to make up for a missed one.
Signs of overdose primarily involve excessive bleeding, which may manifest as unusual bruising, pink or brown urine, red or black tarry stools, or coughing up blood. In the event of a life-threatening overdose, a specific reversal agent called idarucizumab (Praxbind) is available in hospital settings. This agent binds to dabigatran and neutralizes its effect within minutes. If you suspect an overdose, seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as stopping prematurely increases your risk of a stroke or blood clot.
The most frequently reported side effects of dabigatran etexilate involve the gastrointestinal (GI) system and minor bleeding.
Dabigatran etexilate is a high-alert medication because it significantly alters the body's ability to form clots. While this prevents strokes, it also means that any injury can result in excessive bleeding. Patients must be educated on the signs of internal bleeding, which are not always visible. You should inform all healthcare providers, including dentists and surgeons, that you are taking dabigatran etexilate before any procedure is scheduled.
1. Risk of Stroke on Discontinuation: Premature discontinuation of any oral anticoagulant, including dabigatran, increases the risk of thrombotic events (clots). To reduce this risk, consider coverage with another anticoagulant if dabigatran etexilate is discontinued for a reason other than pathological bleeding or completion of a course of therapy.
2. Spinal/Epidural Hematoma Risk: Epidural or spinal hematomas may occur in patients treated with dabigatran etexilate who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Factors that can increase the risk include: use of indwelling epidural catheters, concomitant use of other drugs that affect hemostasis (e.g., NSAIDs, platelet inhibitors), and a history of traumatic or repeated epidural or spinal punctures.
There are specific scenarios where dabigatran etexilate must never be used because the risks far outweigh any potential benefits:
Dabigatran etexilate is classified as a drug that should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. There are no adequate, well-controlled studies in pregnant women. Animal studies have shown increased post-implantation loss and fetal variations. The primary concern is the risk of maternal and fetal hemorrhage (bleeding). If you are pregnant or planning to become pregnant, you must discuss alternative anticoagulants, such as low-molecular-weight heparin, which does not cross the placenta.
It is not known whether dabigatran is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants (specifically bleeding), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Most clinicians recommend avoiding breastfeeding while on dabigatran.
Dabigatran is approved for the treatment and prevention of blood clots in children from birth to <18 years of age. However, it is not approved for stroke prevention in children with heart rhythm issues (which are rare in this age group). Dosing in children is complex and must be managed by a pediatric hematologist. The oral pellet formulation is used for children who cannot swallow capsules, but these pellets must never be mixed with milk or milk products, as this interferes with absorption.
Dabigatran etexilate is a competitive, reversible, direct thrombin inhibitor. Thrombin is a serine protease that plays a central role in the coagulation cascade. It converts fibrinogen to fibrin, activates Factors V, VIII, XI, and XIII, and induces platelet aggregation. Dabigatran binds to the active site of the thrombin molecule, preventing it from interacting with its substrates. Unlike heparin, which requires the cofactor antithrombin III to work, dabigatran binds directly to thrombin. It can inhibit both "free" thrombin circulating in the blood and "clot-bound" thrombin, which is essential for preventing the expansion of existing clots.
There is a close correlation between plasma dabigatran concentrations and the degree of anticoagulant effect. Dabigatran prolongs the Activated Partial Thromboplastin Time (aPTT), Ecarin Clotting Time (ECT), and Thrombin Time (TT). The TT is particularly sensitive and is often too sensitive for routine monitoring. The pharmacodynamic effect is rapid, with anticoagulation achieved within 1 to 2 hours after administration.
| Parameter | Value |
Common questions about Pradaxa
Dabigatran etexilate is primarily used to reduce the risk of stroke and dangerous blood clots in patients with a heart rhythm disorder called non-valvular atrial fibrillation. It is also frequently prescribed to treat deep vein thrombosis (DVT), which are clots in the legs, and pulmonary embolism (PE), which are clots in the lungs. Additionally, it helps prevent these clots from returning after initial treatment. Some patients may also receive it to prevent clots following major hip replacement surgery. It works by blocking thrombin, a key enzyme responsible for blood clotting.
The most common side effects are related to the digestive system and minor bleeding. Many patients experience dyspepsia, which feels like indigestion, stomach pain, or a burning sensation in the upper abdomen. Minor bleeding, such as bruising easily, small cuts taking longer to stop bleeding, or occasional nosebleeds, is also common. Because the medication contains an acid core to help with absorption, it can irritate the stomach lining. If you experience severe stomach pain or signs of major bleeding, like black stools, contact your doctor immediately.
It is generally advised to limit alcohol consumption while taking dabigatran etexilate. Alcohol can irritate the stomach lining, increasing the risk of gastritis and gastrointestinal bleeding, which is already a risk with this medication. Heavy drinking can also impair your balance, increasing the risk of falls and subsequent internal bleeding. Chronic heavy alcohol use may also affect liver function, which can indirectly impact how your blood clots. Always consult your healthcare provider about what amount of alcohol, if any, is safe for your specific health profile.
Dabigatran etexilate is generally not recommended during pregnancy unless the benefits clearly outweigh the risks, as there is a lack of comprehensive data in humans. Animal studies have shown that the drug can cause fetal harm and increase the risk of pregnancy loss. The primary danger to both the mother and the fetus is the risk of severe hemorrhage. If you are of childbearing age, discuss reliable contraception with your doctor. If you become pregnant, you will likely be switched to an injectable anticoagulant like heparin that does not cross the placenta.
Dabigatran etexilate works very quickly compared to older anticoagulants like warfarin. It typically reaches its peak blood concentration and provides full anticoagulation within 1 to 2 hours after the first dose is taken. This rapid onset means that it does not usually require 'bridging' with injectable blood thinners for most conditions, except when treating an active DVT or PE. Because it works so quickly, it also wears off relatively fast, which is why taking your doses on time is critical. If you stop taking it, the protective effect begins to diminish within about 12 to 24 hours.
No, you should never stop taking dabigatran etexilate suddenly without your doctor's explicit instructions. Stopping the medication abruptly significantly increases your risk of having a stroke or a life-threatening blood clot. If you need to stop the medication for a surgery or dental procedure, your doctor will provide a very specific schedule for when to stop and when to restart. In many cases, the drug is only paused for 24 to 48 hours. Always ensure you have a refill ready so you do not miss any doses accidentally.
If you miss a dose, take it as soon as you remember on the same day. However, if your next scheduled dose is less than 6 hours away, you should skip the missed dose entirely and simply take your next dose at the regular time. Never take two doses at once to 'catch up,' as this significantly increases your risk of a dangerous bleeding event. Setting a daily alarm on your phone or using a medication reminder app can help you stay consistent with the twice-daily schedule required for this drug.
Weight gain is not a known or documented side effect of dabigatran etexilate. If you experience sudden weight gain or swelling in your legs while taking this medication, it is more likely related to another underlying condition, such as heart failure or kidney issues, rather than the drug itself. However, some patients may experience bloating or indigestion, which can feel like abdominal heaviness. If you notice significant changes in your weight, you should discuss them with your healthcare provider to determine the cause.
Dabigatran etexilate has several important drug interactions that you must be aware of. It should not be taken with other anticoagulants or most NSAIDs like ibuprofen or naproxen, as these greatly increase bleeding risk. Certain medications for heart rhythm (like dronedarone) or fungal infections (like ketoconazole) can increase dabigatran levels in your blood. Conversely, some drugs like rifampin or the herbal supplement St. John's Wort can make dabigatran less effective. Always provide your doctor and pharmacist with a complete list of all medications and supplements you take.
Yes, generic versions of dabigatran etexilate capsules have been approved by the FDA and are available in many pharmacies. Generic medications are required to have the same active ingredient, strength, and effectiveness as the brand-name version (Pradaxa). Switching to a generic can often reduce your out-of-pocket costs. However, regardless of whether you take the brand or generic, the storage requirements remain the same: you must keep the capsules in their original bottle or blister pack and use them within 4 months of opening the bottle.
Other drugs with the same active ingredient (Dabigatran Etexilate)
> Warning: Stop taking Dabigatran Etexilate and call your doctor immediately if you experience any of these serious symptoms.
With prolonged use, the primary concern remains the cumulative risk of bleeding. Unlike some older drugs, dabigatran etexilate does not have a high risk of liver toxicity or bone density loss. However, patients on long-term therapy must have their kidney function monitored regularly, as any decline in renal health can cause the drug to accumulate in the body, exponentially increasing the risk of a major bleed.
The FDA has issued two critical Black Box Warnings for dabigatran etexilate:
Report any unusual symptoms, especially those related to bleeding or stomach pain, to your healthcare provider immediately. Regular follow-ups are essential to ensure the medication remains safe for you.
While dabigatran does not require the frequent blood tests associated with warfarin (INR), certain monitoring is vital:
Dabigatran etexilate generally does not affect the ability to drive or operate machinery. However, if you experience dizziness or symptoms of anemia (fatigue), use caution until you know how the medication affects you.
Heavy alcohol consumption increases the risk of stomach ulcers and GI bleeding. While a single occasional drink may be permissible for some, you should discuss alcohol use with your doctor, as it can significantly compound the bleeding risks associated with anticoagulants.
Never stop taking dabigatran etexilate without consulting your cardiologist or primary care physician. If the drug is stopped, the protective effect against stroke disappears within 12-24 hours. If you must stop the drug for a medical procedure, your doctor will provide a strict schedule for when to take your last dose and when to resume.
> Important: Discuss all your medical conditions, especially any history of stomach ulcers, kidney disease, or bleeding disorders, with your healthcare provider before starting Dabigatran Etexilate.
For each major interaction, the mechanism usually involves the P-glycoprotein (P-gp) transporter system. P-gp is a pump in the gut that moves drugs back into the intestinal lumen. Inhibiting this pump increases drug absorption (risk of bleed), while inducing it decreases absorption (risk of clot).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter pain relievers can significantly change how safe this drug is for you.
These are conditions where the drug should be used only with extreme caution and frequent monitoring:
There is no known cross-sensitivity between dabigatran and other classes of anticoagulants like heparins or vitamin K antagonists (warfarin). However, patients sensitive to tartaric acid should be aware that it is a component of the capsule formulation.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous bleeding episodes or surgeries, before prescribing Dabigatran Etexilate.
In clinical trials, the risk of bleeding increased with age. Patients over 75 years old have a higher risk of gastrointestinal bleeding compared to younger patients. Additionally, because kidney function naturally declines with age, elderly patients are more likely to have higher levels of the drug in their system. Careful monitoring of renal function and signs of bleeding is mandatory in this population.
Renal function is the most critical factor in dabigatran safety.
Patients with moderate to severe hepatic impairment (Child-Pugh Class B or C) or those with liver disease expected to impact survival were excluded from major trials. Since these patients often have baseline clotting abnormalities, dabigatran is generally not recommended for those with significant liver disease.
> Important: Special populations require individualized medical assessment. Your doctor will tailor your treatment based on these specific biological factors.
| Bioavailability | ~6.5% |
| Protein Binding | ~35% |
| Half-life | 12-17 hours (longer in renal impairment) |
| Tmax | 1-2 hours (delayed by food) |
| Metabolism | Esterase-mediated hydrolysis (Prodrug to Active) |
| Excretion | Renal 80%, Fecal 20% |
Dabigatran etexilate belongs to the Direct Thrombin Inhibitors (DTIs) class. It is categorized as a Direct Oral Anticoagulant (DOAC). Related medications include other DOACs like Apixaban (Eliquis) and Rivaroxaban (Xarelto), although those drugs target Factor Xa rather than Thrombin.